Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Over the long term, broad indices tend to outperform many active strategies due to lower costs and market-wide diversification.
27,915 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
O-I Glass has climbed about 17% over the past year, even as a large fund unloaded roughly $80 million worth of stock....
Michael Saylor rebutted critics of MicroStrategy's Bitcoin sales as BTC slides and the stock falters. He stressed the...
Regencell Bioscience sits in the high-risk, high-reward world of early-stage biotech. Before you consider investing, ...
A rising retirement burden and shifting policy outlook are reshaping how Americans view Social Security. Learn what t...
Visa sits at the center of a rising wave of short bets, even as it preserves a cash-generating moat. The latest data ...
Starting with real estate can feel overwhelming. This guide breaks down the best types rental properties for beginner...
Constellation Energy has closed the Calpine deal and now commands the country’s largest private-sector power fleet, w...
Want a secure retirement? See how the benefits of investing for retirement add up over time. Learn a practical plan, ...
As mid-2026 markets favor steady dividend strategies, the tax-free growth inside a ROTH IRA could reshape the appeal ...
In May, a calmer approach can shine. This article highlights two dividend stocks that are no-brainer buys for conserv...
This guide decodes MKSI's 2026 earnings call, explaining what to watch, how management guidance shapes strategy, and ...